MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
PROTECT-TIMI 30 Trial
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2005-11-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00250471
A Study of MLN8054 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00249301
- Locations
- 🇺🇸
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
- Conditions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00129207
- Locations
- 🇺🇸
Medical Center, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
- Conditions
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2011-02-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00117351
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
- Conditions
- First Posted Date
- 2005-05-20
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Registration Number
- NCT00111319
- Locations
- 🇺🇸
Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
- Conditions
- First Posted Date
- 2004-06-15
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00085696
- Locations
- 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00080405
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
- Conditions
- First Posted Date
- 2003-10-13
- Last Posted Date
- 2007-07-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00070837
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Weill Medical College of Cornell University/ New York Presbyterian Hospital, New York, New York, United States
🇺🇸Duke University Medical Center, Box 3532, Durham, North Carolina, United States
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
- Conditions
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00064636
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
- Conditions
- First Posted Date
- 2003-07-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00064610
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Columbia-Presbyterian Hospital, New York, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States